Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GYM329 for prevention and recovery of disuse muscle atrophy in healthy male volunteers
NL-OMON54969Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in muscle atrophy comparing GYM329 with Placebo (2 arms). Primary endpoints: Percent change in thigh muscle strength score from Day 1 to Day 15 and Percent change in thigh muscle strength score from Day 15 to Day 29. Started Feb 2021; status: active, not recruiting.
02
Drugs
emugrobart
03
Conditions
muscle atrophy
Beyond the preview
Go deeper on NL-OMON54969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54969.